




FIG. 1





FIG. 2






FIG. 4




FIG. 5A




FIG. 5B




FIG. 6A


8/87

ProC440 LC-MS data:

MMP14 cleavage
L161 uPA cleavage: 25145.1 Da
S169

CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSA
AWDETLLDKFYTELYQQLNDLEACVIGQVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVAEIM
RSFSLSTNLQESLRSKESGRSDNICPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVSQEDPEVQ
FNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIKAKGQPREP
QVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSDGSFFLYSRLTVDKSRWQ
QGNVFSCSVMHAEALHNHYTQKSLSLS

FIG. 6B



	ProC440	ProC440+uPA	ProC440+MMP14
EC50	1.861	0.01503	0.009833

FIG. 6C




FIG. 7A




FIG. 7B

12/87

METDTLLLWVLLLWVPGSTG

QSGQTDVDYYREWSWTQVSGSSGGS**LSGRSDNI**IGSGGSCDLPQTHSLGSRRTLMLLAQM
RRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETL
LDKFYTELYQQLNDLEACVIQGVGVTEETPLMKEDSILAVRKYFQRITLYLKEKKYSPCA
WEVVRAEIMRSFSLSTNLQESLRSKE**LSGRSDNI**CPPCPAPEFLGGPSVFLFPPKPKDT
LMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKGLPSSIEKTIISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQQGNVFCSSV
MHEALHNHYTQKSLSLS

(ProC732)

FIG. 8*METDTLLLWVLLLWVPGSTG*

QSGQTDVDYYREWSWTQVSGSSGGS**LSGRSDNI**IGSGGSCDLPQTHSLGSRRTLMLLAQM
RRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETL
LDKFYTELYQQLNDLEACVIQGVGVTEETPLMKEDSILAVRKYFQRITLYLKEKKYSPCA
WEVVRAEIMRSFSLSTNLQESLRSKEESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTL
MISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLH
QDWLNGKEYKCKVSNKGLPSSIEKTIISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLV
KGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQQGNVFCSSVM
HEALHNHYTQKSLSLS

(ProC733)

FIG. 9




FIG. 10A




FIG. 10B




FIG. 11A

Daudi proliferation assay





FIG. 11B

	IFN α -con	ProC440+uPA	PEG-IFN α 2b (Sylatron)	ProC440
Specific activity	$1-2 \times 10^9$ U/mg	3.5×10^8 U/mg	0.7×10^8 U/mg	1.3×10^7 U/mg
Anticipated toxic dose	0.1 mpk *	0.288 mpk	1.43 mpk	7.68 mpk

FIG. 12




FIG. 13A

19/87




FIG. 13B




FIG. 13C

21/87




FIG. 13D




FIG. 14




FIG. 14 (Cont'd)




FIG. 14 (Cont'd)




FIG. 15




FIG. 15 (Cont'd)




FIG. 15 (Cont'd)

**Daudi Cytotox EC50
IFNa2b hlgG4 fusions
111419HA**




FIG. 16




FIG. 17

In vivo efficacy of ProC1023




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19A




FIG. 19B




FIG. 20




FIG. 21




FIG. 21 (Cont'd)




FIG. 22




FIG. 22 (Cont'd)




FIG. 23




FIG. 24A




FIG. 24B




FIG. 24C




FIG. 25




FIG. 26





FIG. 27




FIG. 28





FIG. 29

46/87







FIG. 29 (Cont'd)



48/87

Patient's PBMC



Patient's dissociated tumor





FIG. 30 (Cont'd)




FIG. 31





FIG. 31 (Cont'd)

51/87

**FIG. 31 (Cont'd)**




FIG. 32




FIG. 33A




FIG. 33B




FIG. 34A




FIG. 34B




FIG. 35A




FIG. 35B




FIG. 36




FIG. 37




FIG. 37 (Cont'd)




Fig. 38A




Fig. 38B





Fig. 38C



Ligand	Analyte	k_a (1/Ms)	k_d (1/s)	KD (nM)
ProC440	ProC1718	2.055E+05	2.077E-02	101.1




Fig. 38D




Fig. 39A





Fig. 39B



IFNa2b	1	CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI	60
IFNaAD	1	CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI	60
IFNa2b	61	QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVETETPLMKEDSILAVR	120
IFNaAD	61	QQIFNLF+TKDSSAAWDE LLDKF TELYQQLNDLEACV+Q V ETPLM DSILAV+	120
IFNa2b	121	KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE	165
IFNaAD	121	KYFRRITLYLTEKKYSPCAWEVVRAEIMRSLSLSTNLQERLRRKE	165

L161 (MMP14 cleavage)

L157 & 161 (predicted MMP12 cleavage)

Fig. 39C

66/87




Fig. 39C (Cont'd)




Fig. 40A






Fig. 40B

68/87

**Fig. 40C****Fig. 40D**




Fig. 41A




Fig. 41B

71/87




Fig. 41C




Fig. 42A




Fig. 42B




Fig. 42C




Fig. 43




Fig. 44A

Day 1 vs Day 7




Fig. 44B




Fig. 45




Fig. 46




Fig. 46 (Cont'd)




Fig. 47




Fig. 47 (Cont'd)

	3.75mg/kg	7.5 mg/kg	15 mg/kg	30 mg/kg	60 mg/kg
ProC732 (masked)			tolerated	tolerated	tolerated
ProC286 (unmasked)	tolerated	3/5 survival	0/5 survival		




FIG. 48




FIG. 48 (Cont'd)




Fig. 49




FIG. 50




FIG. 51




FIG. 52




FIG. 53




FIG. 53 (Cont'd)